Bond.az White LogoBond.az Black Logo

Berkshire Hathaway buys Taylor Morrison for $8.5B

Berkshire Hathaway acquires Taylor Morrison for $8.5 billion. The deal is expected to close in H2 2026.

Sophia Anderson
BySophia Anderson- Senior Editor
|
0

Berkshire Hathaway Inc. (NYSE:BRK.A, BRK.B) has reached a definitive agreement to acquire Taylor Morrison Home Corporation (NYSE:TMHC) for $72.50 per share in cash.

The deal values Taylor Morrison at approximately $6.8 billion in equity and $8.5 billion in total enterprise value. The purchase price represents a 24% premium to Taylor Morrison's closing price on May 29, 2026.

Taylor Morrison is a national homebuilder with over 350 communities across 21 markets in 12 states. It serves entry-level, move-up, and resort lifestyle buyers under the Taylor Morrison and Esplanade brands, and develops rental communities under its Yardly brand.

Post-acquisition, Taylor Morrison will continue under its existing management, led by CEO Sheryl Palmer. The company will become private and its stock will be delisted from the NYSE.

"Berkshire is acquiring a best-in-class national homebuilder. Over time, we expect to unify our site-built homebuilding operations into a combined platform," said Berkshire Hathaway CEO Greg Abel.

The transaction is expected to close in the second half of 2026, subject to Taylor Morrison stockholder approval and regulatory clearances.

Goldman Sachs & Co. LLC and Moelis & Company LLC are serving as financial advisors to Taylor Morrison.

More News
Today / 16:31
|
665

iHuman acquires two education apps for $13M

iHuman Inc. acquires All Knowledge and Perfect Lingo education apps for RMB94 million, appoints new executives.

0
Today / 13:02
|
563

Revolution Medicines Phase 3 Trial Results

Revolution Medicines announces positive Phase 3 trial results for daraxonrasib in pancreatic cancer, showing significant survival benefit.

0
Today / 13:01
|
802

Prostate cancer death risk cut by 20% with J&J drug

Johnson & Johnson's apalutamide reduces prostate cancer death risk by 20%, according to Phase 3 trial results.

0
Today / 12:31
|
392

Brenetafusp Shows Promise in Melanoma

Immunocore's brenetafusp showed 14.3-month median overall survival in Phase 1/2 melanoma trial, supporting Phase 3 development.

0
Today / 09:32
|
612

National Vision Q1 2026: margins expand

National Vision Holdings Q1 2026 financial results: revenue $543.9M, margin expansion, 4.5% comparable store sales growth.

0
Yesterday / 15:31
|
753

Mineralys Presents Lorundrostat Data in Kidney Patients

Mineralys (MLYS) reveals new clinical data for lorundrostat showing efficacy in hypertensive patients with chronic kidney disease.

0
Yesterday / 14:31
|
541

Cabometyx Cuts Neuroendocrine Tumor Risk

Exelixis announces Cabometyx reduces neuroendocrine tumor progression risk by 74% in CABINET trial. New data presented at ASCO.

0
Yesterday / 12:32
|
339

Immunome presents phase 3 trial results for desmoid tumor drug

Immunome announces phase 3 results for varegacestat in desmoid tumors: 84% reduction in progression risk, 56% objective response rate.

0
Yesterday / 07:30
|
735

Tesla Faces China Lawsuit Over Full Self-Driving Claims

Tesla faces a consumer lawsuit in China over Full Self-Driving claims. 10 vehicle owners allege misleading advertising and fraud, seeking $583,000 in damages.

0
Yesterday / 03:02
|
322

FCPT to Buy 102 Vet Properties for $268M

Four Corners Property Trust acquires 102 veterinary properties for $268 million. The deal is expected to close in early Q3 2026.

0
Yesterday / 03:00
|
329

Jefferies Starts Merck KGaA at Hold

Jefferies starts Merck KGaA at Hold with a €129 price target, citing balanced valuation and limited upside.

0
2026-05-29 20:05
|
327

Morgan Stanley stock hits all-time high of 208.01 USD

Morgan Stanley stock hits all-time high of 208.01 USD. 62.11% yearly gain, strong earnings, crypto trading on ETrade. Get insights on Bond.az.

0
...
Berkshire Hathaway buys Taylor Morrison for $8.5B | Bond.az